prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 | 29 |30 |31 |32 |33 |34 |35 |36 |37 |38 |39|40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |review

Key Point: The incidence of statin-associated rhabdomyolysis across large clinical trials is <0.1%.

 

Large randomized, controlled trials indicate a low incidence of rhabdomyolysis
with statin therapy.  A recent review of major trials identified only 7 cases of rhabdomyolysis among more than 42,000 patients randomly assigned to
receive statin therapy
1

The reported incidence of fatal rhabdomyolysis with statin therapy is extremely rare—0.15 deaths per 1 million prescriptions2

 

 

 

 

 

References

1. Thompson PD et al. Statin-associated myopathy. JAMA. 2003;289:1681-1690.

2. Staffa JA et al. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539-540.